VEGFA and urinary bladder carcinoma: It has been suggested that the NRP2/VEGF-C axis plays a role in bladder cancer therapy resistance and the VEGF-paxillin-NRP2 pathway could represent a new therapeutic target for cancer and other angiogenesis-related diseases.